The first year of amyloid immunotherapy in an academic dementia specialty practice
Madeline Paczynski, Suzanne E Schindler, Erik S Musiek, David M Holtzman, Tammie LS Benzinger, Alan Dow, Sheyda J Namazie‐Kummer, Zachary J Posey, Carson Woodfin, Dawn Ellington, John C Morris, B Joy Snider · 2025
Read The first year of amyloid immunotherapy in an academic dementia specialty practice by Madeline Paczynski, Suzanne E Schindler, Erik S Musiek, David M Holtzman, Tammie LS Benzinger, Alan Dow, Sheyda J Namazie‐Kummer, Zachary J Posey, Carson Woodfin, Dawn Ellington, John C Morris, B Joy Snider (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712200.txt.
Description
Madeline Paczynski and co-authors describe the first year of amyloid therapy in a US clinic in a 2025 paper. The center is a large academic dementia practice in St Louis. It sees over two thousand memory patients a year.
Amyloid-lowering drugs for early Alzheimer disease raise many practical hurdles. Screening, infusions, scans, and safety checks all need new systems. Leaders prepared for two years before the first patients. Sixteen clinicians carried the service in its first year. The account covers staffing, workflow, and patient selection. Readers planning similar services get a candid playbook from the front line.
Catalog record
| CREATOR | Madeline Paczynski, Suzanne E Schindler, Erik S Musiek, David M Holtzman, Tammie LS Benzinger, Alan Dow, Sheyda J Namazie‐Kummer, Zachary J Posey, Carson Woodfin, Dawn Ellington, John C Morris, B Joy Snider |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |